# Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases:  Guidance for Industry; Availability - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/optimizing-the-dosage-of-human-prescription-drugs-and-biological-products-for-the-treatment-of-oncologic-diseases-guidance-for-industry-availability/65250af0-1be1-43c2-bace-d1002014248b

> FDA guidance document: Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases:  Guidance for Industry; Availability. Issue date: August 08, 2024. Get complete insights and analysis.

---

## Details

- Title: Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases:  Guidance for Industry; Availability
- Communication Type: Guidance Document
- Product Type: other
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2024-08-08
- Last Changed: 2024-08-09
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-2827">FDA-2022-D-2827</a>

## Related Documents

- [Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment:  Guidance for Industry; Availability](https://www.globalkeysolutions.net/guidances/guidance-document/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-guidance-for-industry-availability/7511194b-76aa-4116-a433-198583956923)
- [Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/hematologic-malignancies-regulatory-considerations-for-use-of-minimal-residual-disease-in-development-of-drug-and-biological-products-for-treatment-guidance-for-industry/5e0485fc-a570-4965-bae5-05741639f886)
- [Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-inclusion-of-adolescent-patients-in-adult-oncology-clinical-trials/d9024369-3d11-4161-a606-70ab031e8871)